- Coordinator
- Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna, Italy
- Runs
- 1 October 2025 to 31 March 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101213190
What the project is doing
In the project's own words, from its summary on CORDIS.
SOFTINVADERS aims at advancing the technology readiness of the microrobots prototypes developed in the ERC-funded project CELLOIDS, paving the way to their future clinical translation. In CELLOIDS, we have developed the first ultra-soft microrobots and observed that they can move through gaps narrower than their size under magnetic actuation. The microrobots have a cell-like body consisting of a Giant Unilamellar Vesicle – an aqueous liquid interior enclosed by a nanometres-thin membrane made of a phospholipid bilayer.
This allows them to deform substantially and even form thin protrusions, squeezing through narrow gaps and between obstacles. Such ultra-soft microrobots have the potential to traverse body tissues, mimicking the interstitial migration of leukocytes. SOFTINVADERS will challenge our microrobots with the daunting task of penetrating a solid tumour. This could open new opportunities for administering anti-cancer therapeutics in situ.
The translation from research towards innovation will be achieved by addressing three main objectives: (i) enhancing the capabilities and magnetic actuation of our microrobots to make them suited to tumour infiltration; (ii) developing realistic in-vitro tumour models for the validation of microrobots; (iii) establishing a research collaboration with a clinical partner to guide the design of anti-cancer ultra-soft microrobots and define an innovation strategy.
If successful, SOFTINVADERS will provide a preliminary validation of tumour infiltration by synthetic magnetic microrobots. This will represent the first innovation step towards the realisation of microrobots-enabled in-situ administration of anti-cancer therapies, potentially leading to improved therapeutic outcomes and better life quality for millions of patients worldwide.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna | Pisa | Italy | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI